期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

切除修复交叉互补基因1与铂类耐药

Excision repair cross-completion 1 and platinum resistance
原文传递
导出
摘要 切除修复交叉互补基因1（excision repair cross-completion1,ERCC1）是DNA修复的重要因子之一,而DNA修复参与了铂类药物耐药的形成,ERCC1表达增高和其多态性均与铂类耐药有关,用药物干预或基因封闭技术抑制ERCC1表达能在一定程度上逆转铂类耐药。 Excision repair cross-completion 1（ERCC1） is one of the important factors in the repair of the cisplatin-DNA adducts, which is reported to be related to the level of platinum resistance in tumor cells. The level of ERCC1 expression and its polymorphism are all correlated with the platinum resistance, and drug interference or gene-targeted blocking can reverse the the resistance to platinum.
作者 夏莹 胡成平
机构地区 长沙市中心医院胸科 中南大学湘雅医院呼吸科
出处 《国际呼吸杂志》 2007年第16期1245-1248,共4页 International Journal of Respiration
关键词 切除修复交叉互补基因1 DNA修复 核苷酸切除修复 铂类耐药 Excision repair cross-completion 1 gene DNA repair Nucleotide excission repai Platinum resistance
分类号 R4 [医药卫生—临床医学]
  • 相关文献

参考文献26

  • 1Bermstein C, Bernstein H, Payne CM, et al. DNA repair/proapoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutr Res, 2002,511 : 145-178.
  • 2Selfridge J, Hsia KT, Redhead NJ, et al. Correction of liver dysfunction in DNA repair-deficient mice with an ERCC1 transgene. Nucleic Acids Res,2001,29:4541-4550.
  • 3Kuraoka I, Kobertz WR, Ariza RR, et al. Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/ recombinatein nuclease. J Biol Chem,2000,275:26632-26636.
  • 4Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res,2002,8:2286-2291.
  • 5Rosell R, Taron M, Alberola V, et al. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer, 2003, 41 : 1123-1128.
  • 6Rosell R,FelipE,Taron M,et al. Gene expression as a predictive marker of outcome in stage Ⅱ B-ⅣA-ⅢB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res, 2004,15 : 4215-419.
  • 7Rosell R,Cuello M,Cecere F, et al. Treatment of non-small-cell lung cancer and pharmacogenomics:where we are and where we are going. Curr Opin Oncol, 2006,18:135-143.
  • 8Dabholkar M,Thormton K, Wionnet L, et al. Increased mRNA level of xeroderma pigmentosum comp!etmentation group B (XPB) and Cockayne's syndrome complementation group(CSB) without increased mRNA levels of multidrug-resistanct human ovarian cancer tissues. Biochem Pharmacol, 2000, 60: 1611- 1619.
  • 9Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol, 2000,60 : 1305-1313.
  • 10Selvakumanran M,Pisarcik DA,Bao R, et al. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer. Res, 2003,63 : 1311-1316.

二级参考文献10

  • 1Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy[J]. J Clin Oncol,1998,
  • 2Yen L, Woo A, Christopoulopoulos G, et al. Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents[ J ].Mutar Res, 1995, 337(3): 179-189.
  • 3Dunkern TR, Fritz G, Kaina B. Cisplatin-induced apoptosis in 43-3B and 27-1 cells defective in nucleotide excision repair[ J].Mutat Res, 2001, 486(4): 249-258.
  • 4Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: Role of ERCC1-XPF[J]. Biochem Pharmacol, 2000, 60(9): 1305-1313.
  • 5Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy[ J ]. Cancer Treat Rev,1998, 24(5): 331-344.
  • 6Damia G, Guidi G, D' Inca Ici M. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines[J]. Eur J Cancer, 1998, 34( 11 ):1783-1788.
  • 7Petit C, Sancar A. Nucleotide excision repair: From E. coli to man[J]. Biochimie, 1999, 81(1-2): 15-25.
  • 8Wood RD, Mitchell M, Sgouros J, et al. Human DNA repair genes[ J]. Science, 2001,291 (5507): 1284-1289.
  • 9Zeng-Rong N, Paterson J, Alpert L, et al. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy [ J ]. Cancer Res, 1995, 1315 ( 55 ): 4760-4764.
  • 10Britten RA, Liu D, Tessier A, et al. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells [J]. Int J Cancer, 2000, 89(5): 453-457.

共引文献13

国际呼吸杂志
2007年 第16期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部